



Interreg



Cofinancé par
l'Union Européenne
Medegefinancierd door
de Europese Unie

France - Wallonie - Vlaanderen



CrossS3
ALCOVE

ALCOVE: Towards an innovative cross-border lung cancer screening

Dear Sir, Madam,

We are delighted to invite you to the kick-off event of ALCOVE INTERREG project which aims to redefine lung cancer screening. Coordinated by Lille University Hospital, the project is managed by Prof. Sebastien Hulo from the Functional Respiratory Investigation Unit of the Heart & Lung Institute.



Date: March 31 st 2025



Timetable: 10.00am - 2.00pm



**Location: Centre Hospitalier Universitaire (CHU) de Lille,
Auditorium A, Institut Gernez Rieux**



Register now

Event free of charge, registration is mandatory.

This event will provide a unique opportunity to:

- Understand the context of organised lung cancer screening in the cross-border region and ALCOVE's positioning.
- Discuss challenges and implementation perspectives with external stakeholders and project partners
- Find out about project's main challenges in providing access to more effective screening for populations at risk.
- Take part in strategic debates and discussions on the future of lung cancer screening in France and Belgium.

A programme featuring:

- **Key presentations on the project and lung cancer context**
- **Talks by our partners**
- **A panel discussion** on cross-border challenges of lung cancer screening
- **Netwerkmogelijkheden tijdens de lunch.**

ALCOVE:

ALCOVE project – redefining lung cancer screening – aims to improve the management of patients with lung cancer, which is often diagnosed at an already late stage, by promoting an accessible early detection solution. The project ALCOVE develops a non-invasive detection method based on the analysis of volatile organic compounds (VOCs) in the exhaled breath using a unique device: the electronic nose.

Supported by a cross-border consortium of 17 partners from Hauts-de-France, Grand-Est, Wallonia and Flanders, the project is part of a scientific and medical cooperation initiative. Objectives include the miniaturisation and clinical validation of this prototype electronic nose to then make it operational and available to healthcare professionals from the region.

Our project aims at reducing barriers to screening, improve early detection of lung cancer and ease future integration of the electronic nose in clinical routine and screening programmes.

ALCOVE is funded by the European Interreg France-Wallonia-Flanders programme (2024-2028) via the ERDF for a total €6.6m.

We look forward to welcoming you there!

ALCOVE's team



In samenwerking met academische, klinische en industriële spelers



Met de medewerking van



*You are receiving this email because you are part of our network.
If you no longer wish to receive our messages, please click here.*

Over ALCOVE

ALCOVE aims to facilitate the early detection of lung cancer through the use of an accessible, non-invasive device. ALCOVE is funded by the European Interreg France-Wallonia-Flanders program (2024-2028) through the ERDF and has a total budget of €6.6 million.

Contact: Prof. Sébastien HULO | sebastien.hulo@chu-lille.fr